Current Neurology and Neuroscience Reports

, Volume 1, Issue 3, pp 277–285

Immunologic therapy for relapsing-remitting multiple sclerosis

  • Heather J. MacLean
  • Mark S. Freedman


The treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis, has been revolutionized in recent years. In addition to effective treatment of acute relapses, therapies are now available to prevent relapses, reduce the burden of disease as seen on magnetic resonance imaging, and possibly even slow the course of disease. There are now several agents either approved, awaiting approval, or in various stages of development in many countries. Evidence suggests that early intervention with these agents will yield the best results in the long run. The current approach to treatment of RRMS is the focus of this discussion.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Schumacher GA, Beebe G, Kubler et al.: Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965, 122:522–568.Google Scholar
  2. 2.
    Poser CM, Paty DW, Sheinberg L, et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227–231.PubMedCrossRefGoogle Scholar
  3. 3.
    Thompson AJ, Polman CH, Miller DH, et al.: Primary progressive multiple sclerosis. Brain 1997, 120:1085–1096.PubMedCrossRefGoogle Scholar
  4. 4.
    Weinshenker BG, Bass GP, Rice G, et al.: The natural history of multiple sclerosis: a geographically based study. Brain 1989, 112:133–146.PubMedCrossRefGoogle Scholar
  5. 5.
    Broman T, Andersen O, Bergmann L: Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand 1981, 63:6–33.PubMedGoogle Scholar
  6. 6.
    Confavreux C, Vukusic S, Moreau T, Adeleine P: Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343:1430–1438. This papers suggests a dissociation between progression of disability and relapses.PubMedCrossRefGoogle Scholar
  7. 7.
    Sorensen TL, Ransohoff RM: Etiology and pathogenesis of multiple sclerosis. Sem Neurol 1998, 18:287–293.Google Scholar
  8. 8.
    Lucchinetti CF, Brueck W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707–717. There is growing evidence that multiple sclerosis may not be a single disease entity. Different clinical courses may be produced by different pathologic mechanisms. Even patients with similar courses may have different pathologies.PubMedCrossRefGoogle Scholar
  9. 9.
    Crockard AD, Treacy MT, Droogan AG, et al.: Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis. Mult Scler 1995, 1:20–24.PubMedGoogle Scholar
  10. 10.
    Miller DH, Thompson AJ, Morrissey SP, et al.: High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neur Neurosurg Psychol 1992, 55:450–453.CrossRefGoogle Scholar
  11. 11.
    Barkhof R, Tas MW, Frequin ST, et al.: Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994, 36:382–387.PubMedCrossRefGoogle Scholar
  12. 12.
    Reder AT, Thapar M, Jensen MA: A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology 1994, 44:2289–2294.PubMedGoogle Scholar
  13. 13.
    Beck RW, Cleary PA, Malcolm M, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581–588.PubMedCrossRefGoogle Scholar
  14. 14.
    Goodkin DE, Kindel RP, Weinstock-Guttman B, et al.: A phase II study of IV methylprednisolone in secondary progressive multiple sclerosis. Neurology 1998, 51:239–245.PubMedCrossRefGoogle Scholar
  15. 15.
    Selleberg F, Frederisken JL, Nielsen PM, Olesen J: Double blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998, 51:529–534.Google Scholar
  16. 16.
    Barnes D, Hughes RA, Morris RW, et al.: Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997, 349:902–906.PubMedCrossRefGoogle Scholar
  17. 17.
    Metz LM, Sabuda D, Enns R, et al.: Safety and tolerability of high-dose oral prednisone in the treatment of multiple sclerosis. Neurology 1998, 50:A63.Google Scholar
  18. 18.
    Weinshenker BG, O’Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878–886. Prior to this publication, it was unknown whether any treatment was of benefit once steroids failed to improve a clinical attack. This evidence provides us with a rational treatment approach to steroidresistant severe attacks.PubMedCrossRefGoogle Scholar
  19. 19.
    The INFB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995, 45:1277–1285.Google Scholar
  20. 20.
    Wee Yong V, Chabot S, Stuve O, Williams G: Interferon beta in the treatment of multiple sclerosis; mechanisms of action. Neurology 1998, 51:682–689.Google Scholar
  21. 21.
    Kappos L, and the European Study Group on Interferon b-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491–1497.CrossRefGoogle Scholar
  22. 22.
    Jacobs LD, Cookfair D, Rudick RA, et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285–294.PubMedCrossRefGoogle Scholar
  23. 23.
    PRISMS Study Group: Randomised double-blind placebocontrolled study of interferon B-1a in relapsing-remitting multiple sclerosis. Lancet 1998, 352:1498–1504.CrossRefGoogle Scholar
  24. 24.
    Li DK, Paty DW, UBC MS/MRI Analysis Research Group, and PRISMS Study Group: Magnetic resonance imaging results of the PRISMS trial: a randomized, double blind, placebo-controlled study of interferon-B1a in relapsingremitting multiple sclerosis. Ann Neurol 1999, 46:197–206.PubMedCrossRefGoogle Scholar
  25. 25.
    Feldmann R, Low-Weiser H, Duschet P, Gschnait F: Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. Dermatology 1997, 195:52–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Monzani F, Caraccio N, Casolaro A, et al.: Long-term interferon beta-1b therapy for MS: is routine thyroid assessment always useful? Neurology 2000, 55:549–552.PubMedGoogle Scholar
  27. 27.
    Ross C, Clemmesen KM, Svenson M, et al.: Immunogenicity of interferon-[beta] in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000, 48:706–712.PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson KP, Brooks BR, Cohen JA, et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicentre, double blind, placebo-controlled trial. Neurology 1995, 45:1268–1276.PubMedGoogle Scholar
  29. 29.
    Aharoni R, Teitelbaum D, Sela M, Arnon R: Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1997, 94:10821–10826.PubMedCrossRefGoogle Scholar
  30. 30.
    Aharoni R, Teitelbaum D, Leitner O, et al.: Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A 2000, 97:11472–11477. This interesting paper provides evidence for the purported mechanism of action of glatiramer acetate, at least in an established animal model of experimental allergic encephalitis.PubMedCrossRefGoogle Scholar
  31. 31.
    Johnson KP, Brooks BR, Ford CC, et al.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000, 6:255–266. This study provides evidence of sustained benefit of glatiramer acetate for at least 6 years.PubMedGoogle Scholar
  32. 32.
    Stangel M, Toyka KV, Gold R: Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 1999, 56:661–663.PubMedCrossRefGoogle Scholar
  33. 33.
    Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al.: Randomized placebo-controlled trial of monthly intravenous immunoglobulins therapy in relapsing-remitting multiple sclerosis. Lancet 1997, 349:589–593.PubMedCrossRefGoogle Scholar
  34. 34.
    Lisak RP: Intravenous immunoglobulins in multiple sclerosis. Neurology 1998, 51(suppl_5):S25-S29.PubMedGoogle Scholar
  35. 35.
    Yudkin PL, Ellison GW, Ghezzi A, et al.: Overview of azathioprine in multiple sclerosis. Lancet 1991, 338:1051–1055.PubMedCrossRefGoogle Scholar
  36. 36.
    Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al.: Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30–40.PubMedCrossRefGoogle Scholar
  37. 37.
    Weinstock-Guttman B, Kinkel RP, Cohen JA, et al.: Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist 1997, 3:178–185.CrossRefGoogle Scholar
  38. 38.
    Oger J, Freedman MS: Consensus statement of the Canadian MS Clinics Network on the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 1999, 26:274–275.PubMedGoogle Scholar
  39. 39.
    Rudick RA, Cohen JA, Weinstock-Guttman B, et al.: Management of multiple sclerosis. N Engl J Med 1997, 337:1604–1612.PubMedCrossRefGoogle Scholar
  40. 40.
    Paty DW, Hartung HP: Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol 1999, 6(suppl 1):S1-S35.Google Scholar
  41. 41.
    Optic Neuritis Study Group: The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology 1997, 49:1404–1413.Google Scholar
  42. 42.
    Filippi M, Horsfield MA, Morrissey SP, et al.: Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994, 44:635–641.PubMedGoogle Scholar
  43. 43.
    Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000, 343:898–904. This study, as well as ETOMS (see reference cited in text), supports the early institution of disease-modifying therapy.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2001

Authors and Affiliations

  • Heather J. MacLean
    • 1
  • Mark S. Freedman
    • 1
  1. 1.Multiple Sclerosis ClinicUniversity of Ottawa, The Ottawa Hospital-General CampusOttawaCanada

Personalised recommendations